Skip to main content
SpringerLink
Log in

Method of Presenting Oncology Treatment Outcomes Influences Patient Treatment Decision-Making in Metastatic Colorectal Cancer

  • Original Article
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The methods used to communicate relevant outcomes in oncology to patients will likely influence treatment decisions. The purpose of this study was to examine the influence of three different methods of describing the efficacy of therapy on treatment decisions regarding management of metastatic colorectal cancer.

Methods

Participants reviewed a clinical scenario and randomly received one of three ways of describing efficacy of chemotherapy in metastatic colorectal cancer: (1) relative risk reduction, (2) tumor response rate, and (3) median overall survival. They received the same clinical scenario but were presented four treatment options: (1) observation and supportive care, (2) chemotherapy, (3) surgery, and (4) surgery and chemotherapy and the accompanying median overall survival estimate.

Results

Participants included 102 preclinical medical students. In the first scenario, 85% chose chemotherapy in the relative risk reduction group, as did 88% of the tumor response rate group, but significantly fewer participants did so in the median overall survival group (35%; P < .001). In the second scenario, there was a significant difference in treatment preferences, with 4% of participants choosing observation/supportive care. None chose chemotherapy only, 19% chose surgery only, and 77% chose surgery plus chemotherapy (P < .001).

Conclusions

This study demonstrated that different methods of describing oncology treatment outcomes associated with therapy for metastatic colorectal cancer to the liver can have a dramatic effect on patient treatment decisions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ramsey SD, Mandelson MT, Berry K, Etzioni R, Harrison R. Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer. Gastroenterology 2003;125:1645–50

    Article  Google Scholar 

  2. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938–46

    Article  CAS  Google Scholar 

  3. Rothman AJ, Kiviniemi MT. Treating people with information: an analysis and review of approaches to communicating health risk information. J Natl Cancer Inst Monogr 1999;25:44–51

    Article  Google Scholar 

  4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905–14

    Article  CAS  Google Scholar 

  5. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:1338–42

    Article  CAS  Google Scholar 

  6. Engstrom PF, Saltz LB. Update: colorectal cancer guidelines. J Natl Compr Cancer Network 2003;1:9–16

    Google Scholar 

  7. Bilchik AJ, Wood TF, Allegra D, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg 2000;135:657–62

    Article  CAS  Google Scholar 

  8. Weber SM, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 2000;7:643–50

    Article  CAS  Google Scholar 

  9. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309–18

    Article  CAS  Google Scholar 

  10. Bremnes RM, Andersen K, Wist EA. Cancer patients, doctors, nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer 1995;31A:1955–9

    Article  CAS  Google Scholar 

  11. Bremnes RM. Experience with and attitudes to chemotherapy among newly employed nurses in oncological and surgical departments: a longitudinal study. Support Care Cancer 1999;7:11–6

    Article  CAS  Google Scholar 

  12. Jansen SJ, Kievit J, Nooij MA, Stiggelbout AM. Stability of patients’ preferences for chemotherapy: the impact of experience. Med Decis Making 2001;21:295–306

    Article  CAS  Google Scholar 

  13. Jansen SJ, Kievit J, Nooij MA, et al. Patients’ preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer 2001;84:1577–85

    Article  CAS  Google Scholar 

  14. McQuellon RP, Muss HB, Hoffman SL, Russell G, Craven B, Yellen SB. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 1995;13:858–68

    Article  CAS  Google Scholar 

  15. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990;300:1458–60

    Article  CAS  Google Scholar 

  16. Piga A, Graziano F, Zahra G, Cellerino R. Attitudes of non-oncology physicians dealing with cancer patients. A survey based on clinical scenarios in Ancona province, central Italy. Tumori 1996;82:423–9

    Article  CAS  Google Scholar 

  17. Elger BS, Harding TW. Should cancer patients be informed about their diagnosis and prognosis? Future doctors and lawyers differ. J Med Ethics 2002;28:258–65

    Article  Google Scholar 

  18. Rodriguez-Marin J, Lopez-Roig S, Pastor MA. Doctors’ decision-making on giving information to cancer patients. Psychol Health 1996;11:839–44

    Article  CAS  Google Scholar 

  19. Chao C, Studts JL, Abell T, et al. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making. J Clin Oncol 2003;21:4299–305

    Article  Google Scholar 

  20. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413–8

    Article  CAS  Google Scholar 

  21. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77:1254–62

    Article  CAS  Google Scholar 

  22. Rougier P, Milan C, Lazorthes F, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Francaise de Cancerologie Digestive. Br J Surg 1995;82:1397–400

    Article  CAS  Google Scholar 

  23. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19:59–71

    Article  CAS  Google Scholar 

  24. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991;110:13–29

    CAS  PubMed  Google Scholar 

  25. Rougier P, Milan C, Lazorthes F, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Francaise de Cancerologie Digestive. Br J Surg 1995;82:1397–400

    Article  CAS  Google Scholar 

  26. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413–8

    Article  CAS  Google Scholar 

  27. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77:1254–62

    Article  CAS  Google Scholar 

  28. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991;110:13–29

    CAS  PubMed  Google Scholar 

  29. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039–48

    Article  CAS  Google Scholar 

  30. Flesch R. A new readability yardstick. J Appl Psychol 1948;32:221–33

    Article  CAS  Google Scholar 

  31. Sonpavde G. Communicating the value of adjuvant chemotherapy. J Clin Oncol 2003;21:948–9

    Article  Google Scholar 

  32. Weinfurt KP, Depuy V, Castel LD, Sulmasy DP, Schulman KA, Meropol NJ. Understanding of an aggregate probability statement by patients who are offered participation in phase I clinical trials. Cancer 2005;103:140–7.

    Article  Google Scholar 

  33. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:1338–42

    Article  CAS  Google Scholar 

  34. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905–14

    Article  CAS  Google Scholar 

  35. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol 2002;20:1499–505

    PubMed  Google Scholar 

  36. Fong Y, Blumgart LH, Cohen A, Fortner J, Brennan MF. Repeat hepatic resections for metastatic colorectal cancer. Ann Surg 1994;220:657–62

    Article  CAS  Google Scholar 

  37. Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002;235:863–71

    Article  Google Scholar 

  38. Nordlinger B, Rougier P. Liver metastases from colorectal cancer: the turning point. J Clin Oncol 2002;20:1442–5

    Article  Google Scholar 

  39. Chao C, Studts JL, Abell T, et al. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making. J Clin Oncol 2003;21:4299–305

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, University of Louisville School of Medicine, 315 East Broadway, Room 313, Louisville, Kentucky, 40202

    Robert C. G. Martin II MD

  2. Department of Medicine and Behavioral Oncology Program, James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, 40202

    Jamie L. Studts PhD

  3. Department of Psychological and Brain Sciences, University of Louisville School of Medicine, Louisville, Kentucky, 40202

    Sheri A. McGuffin MAE & Lynne M. Roetzer BA

  4. Abell Research Consulting, Ouray, Colorado, 81427

    Troy D. Abell PhD, MPH

Authors
  1. Robert C. G. Martin II MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheri A. McGuffin MAE
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lynne M. Roetzer BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Troy D. Abell PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jamie L. Studts PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert C. G. Martin II MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, R.C.G., McGuffin, S.A., Roetzer, L.M. et al. Method of Presenting Oncology Treatment Outcomes Influences Patient Treatment Decision-Making in Metastatic Colorectal Cancer. Ann Surg Oncol 13, 86–95 (2006). https://doi.org/10.1245/ASO.2006.03.086

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2006.03.086

Keywords

Search

Navigation